US Patent

US12178919 — Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof

Method of Use · Assigned to Impax Laboratories LLC · Expires 2034-10-07 · 8y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa for oral use.

USPTO Abstract

The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-219 — Sinemet Cr
U-219 — Sinemet Cr
U-219 — Sinemet Cr
U-219 — Sinemet Cr

Patent Metadata

Patent number
US12178919
Jurisdiction
US
Classification
Method of Use
Expires
2034-10-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Impax Laboratories LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.